* FOVEA PHARMACEUTICALS *
2005 - IDF
Paris
www.fovea-pharma.com Discovery, Drugs
Key words: Ophthalmology, Allergy conjunctivitis, Mavular edema, Retinitis pigmentosa
Mission: to discover and develop new treatments focused on ocular diseases (dry eye, age-related macular degeneration, retinitis pigmentosa, diabetic retinopathy), with a special focus on retinal pathologies
Clients: Pharmaceutical industry (own development, up to preclinical)
info@fovea-pharma.com
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS | | Start-up |
Managing Dir.: Gilly (Bernard) [born 1957, Ph.D. bioeconomy, ex-Sofinnova, Transgene (CEO), Pasteur-Mérieux-Connaught]Sc.Dir.:
Fin.Dir.: Davitian (Bernard) [born 1960, MBA, ex-Neurotech (CEO), Transgene, Pasteur-Mérieux]
Oper.Dir.: Bélichard (Pierre) [ex-Urogene, Ethypharm, Fournier]
BusDev: Sternberg (Garry) [M.D., MBA, ex-Eyetech, BMS]
Financers: Sofinnova Partners, CAPE, Abingsworth Mangement, The Wellcome Trust, GIMV | Turnover (M€) : 0.005 (2006)
Total funding (M€) : 50.5
Last funding (M€) : 30.0
Focus : Ophthalmo
Position : Preclin
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME | | 2007 .12 | 2nd round-financing : 30.0 M€, by previous shareholders | RFINB | [2 years] |
| 2007 .11 | Partnering research agreement with Genzyme | R&D | [2 years] |
| 2005 .11 | 1st round-financing : 20.5 M€, by Sofinnova Partners, CAPE, Abingsworth Management, The Wellcome Trust, GIMV | RFINA | [0 year] |
| 2005 .05 | Company founded by Bernard Gilly, Pierre Bélichard, Prof. José-Alain Sahel (professor, Ophthalmology), based on platform from INSERM research unit 592 | ORGF | [0 year] | Actualisation / Updating: 31-Oct-2008 |
|
